Cervical cancer screening in low- and middle-income countries

Mount Sinai Journal of Medicine

Volumn 78, Issue 3, 2011, Pages 319-326

  Ditzian, Lauren R ^b   David West, Gizelka ^a   Maza, Mauricio ^b   Hartmann, Beatrix ^b   Shirazian, Taraneh ^a   Cremer, Miriam ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Basic Health International   (El Salvador)

Author keywords

cervical cancer screening; cytology; HPV testing; low resource settings; Pap test; visual inspection with acetic acid

Indexed keywords

ACETIC ACID; VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CYTOLOGY; FEMALE; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; MIDDLE INCOME COUNTRY; PAPANICOLAOU TEST; SOCIAL STATUS; UTERINE CERVIX CANCER; WART VIRUS;

ACETIC ACID; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; EL SALVADOR; FEMALE; GENETIC TESTING; HUMANS; LATIN AMERICA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POVERTY; SOCIOECONOMIC FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79956365862     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20263     Document Type: Article

References (43)

1. Laara E, Day NE, Hakama M., Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247-1249. (Pubitemid 17070815)
2. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Lazcano-Ponce E, Lörinz AT, Salmerõn J, et al., A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control 2010; 21: 1693-1700.
4. Arbyn M, Sankaranarayanan R, Muwonge R, et al., Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123: 153-160. (Pubitemid 351705203)
5. Perkins RB, Langrish SM, Stern LJ, et al., Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned? Trop Med Int Health 2007; 12: 1018-1025. (Pubitemid 47414940)
6. Murillo R, Almonte M, Pereira A, et al., Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008; 26 suppl 11 L37-L48.
7. Sepulveda C, Prado R., Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev 2005; 29: 405-411. (Pubitemid 41406134)
8. Perkins RB, Langrish SM, Stern LJ, et al., Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues 2010; 20: 35-42.
9. Gage JC, Ferreccio C, Gonzales M, et al., Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev 2003; 27: 466-471. (Pubitemid 37506961)
10. Kawonga M, Fonn S., Achieving effective cervical screening coverage in South Africa through human resources and health systems development. Reprod Health Matters 2008; 16: 32-40.
11. Howe SL, Vargas DE, Granada D, et al., Cervical cancer prevention in remote rural Nicaragua: a program evaluation. Gynecol Oncol 2005; 99 3 suppl 1 S232-S235. (Pubitemid 41774356)
12. Agurto I, Sandoval J, De La Rosa M, et al., Improving cervical cancer prevention in a developing country. Int J Qual Health Care 2006; 18: 81-86.
13. Sankaranarayanan R, Esmy PO, Rajkumar R, et al., Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406. (Pubitemid 47176655)
14. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-1394.
15. Palanuwong B., Alternative cervical cancer prevention in low-resource settings: experiences of visual inspection by acetic acid with single-visit approach in the first five provinces of Thailand. Aust N Z J Obstet Gynaecol 2007; 47: 54-60. (Pubitemid 46152472)
16. Sanghvi H, Limpaphayom KK, Plotkin M, et al., Cervical cancer screening using visual inspection with acetic acid: operational experiences from Ghana and Thailand. Reprod Health Matters 2008; 16: 67-77.
17. Goldhaber-Fiebert JD, Denny LE, De Souza M, et al., The costs of reducing loss to follow-up in South African cervical cancer screening. Cost Eff Resour Alloc 2005; 3: 11.
18. Chumworathayi B, Blumenthal PD, Limpaphayom KK, et al., Effect of single-visit VIA and cryotherapy cervical cancer prevention program in Roi Et, Thailand: a preliminary report. J Obstet Gynaecol Res 2010; 36: 79-85.
19. Murillo R, Luna J, Gamboa O, et al., Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet 2010; 109: 230-234.
20. Blumenthal, PD, Gaffikin L., Cervical cancer prevention: making programs more appropriate and pragmatic. JAMA 2005; 294: 2225-2228. (Pubitemid 41571142)
21. Almonte M, Ferreccio C, Winkler JL, et al., Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007; 121: 796-802. (Pubitemid 47106209)
22. Gaffikin L, McGrath JA, Arbyn M, et al., Visual inspection with acetic acid as a cervical cancer test: accuracy validated using latent class analysis. BMC Med Res Methodol 2007; 7: 36.
23. Sellors JW, Jeronimo J, Sankaranarayanan R, et al., Assessment of the cervix after acetic acid wash: inter-rater agreement using photographs. Obstet Gynecol 2002; 99: 635-640. (Pubitemid 34246304)
24. Sherigar B, Dalal A, Durdi G, et al., Cervical cancer screening by visual inspection with acetic acid-interobserver variability between nurse and physician. Asian Pac J Cancer Prev 2010; 11: 619-622.
25. Vedantham H, Silver MI, Kalpana B, et al. CATCH Study Team. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev 2010; 19: 1373-1380.
26. Longatto-Filho A, Erzen M, Branca M, et al., Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening Study. Int J Gynecol Cancer 2006; 16: 955-962. (Pubitemid 43886710)
27. World Health Organization. New Options for Cervical Cancer Screening and Treatment in Low-Resource Settings. Geneva: World Health Organization; 2010.
28. Qiao YL, Sellors JW, Eder PS, et al., A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936.
29. Schiffman M, Herrero R, Hildesheim A, et al., HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 87-93. (Pubitemid 30038388)
30. Schiffman M, Castle PE., The promise of global cervical-cancer prevention. N Engl J Med 2005; 353: 2101-2104. (Pubitemid 41653100)
31. Goldhaber-Fiebert JD, Goldie SJ., Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006; 4: 13.
32. Levin CE, Sellors J, Shi JF, et al., Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer 2010; 127: 1404-1411.
33. Petignat P, Faltin DL, Bruchim I, et al., Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007; 105: 530-535. (Pubitemid 46590347)
34. Ogilvie GS, Patrick DM, Schulzer M, et al., Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005; 81: 207-212. (Pubitemid 40835044)
35. Balasubramanian A, Kulasingam SL, Baer A, et al., Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis 2010; 14: 185-195.
36. Pengsaa P, Sriamporn S, Kritpetcharat O, et al., A comparison of cytology with Pap smears taken by a gynecologist and with a self-sampling device. Asian Pac J Cancer Prev 2003; 4: 99-102.
37. Barbee L, Kobetz E, Menard J, et al., Assessing the acceptability of self-sampling for HPV among Haitian immigrant women: CBPR in action. Cancer Causes Control 2010; 21: 421-431.
38. Sherman ME, Lorincz AT, Scott Dr, et al., Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46-52. (Pubitemid 36124295)
39. Denny L, Kuhn L, Hu CC, et al., Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010; 102: 1557-1567.
40. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
41. Goldie SJ, O'Shea M, Diaz M, et al., Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16: 86-96.
42. Goldie SJ, O'Shea M, Campos NG, et al., Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26: 4080-4093.
43. Gage JC, Castle PE., Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst 2010; 102: 1524-1527.